FAS and gastrointestinal stromal tumor: In our patient cohort, which was representative for an unselected GIST population with regard to sex, age, tumour localisation, histology, risk classification, and KIT exon 11 mutations (Corless et al, 2004; Nilsson et al, 2005), Fas and FasL were abundantly expressed.